This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter H. Slugg, MD
Princeton, NJ

Marcus Haug, PharmD, MSc
Cleveland, Ohio

Arch Intern Med. 1994;154(3):343-347.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In response to the letter by McIsaac regarding our study of ranitidine-associated central nervous system adverse drug reactions (CNS-ADRs),¹ first of all, it is important to focus on the questions and issues examined by our studies dealing with complex problems in patients hospitalized in an intensive care unit, as contrasted with the use of ranitidine in an outpatient setting in otherwise healthy patients. It is clear that ranitidine is associated with CNS-ADRs.² In contrast to their data on file concerning general use of ranitidine, our study, in addition, documents a much higher incidence of CNS-ADRs while patients are receiving ranitidine and are hospitalized in an intensive care unit, and further, that the occurrence is related to the level of renal function.

This was a clinical study, of known high-risk patients in whom we evaluated and carefully documented CNS-ADRs. An estimate of patient numbers necessary for valid statistical evaluation . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?